[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1734 Engrossed Amendment Senate (EAS)]

<DOC>
  
  
  
  
  
  
  
  
  
  

                  In the Senate of the United States,

                                                         June 22, 2023.
    Resolved, That the bill from the House of Representatives (H.R. 
1734) entitled ``An Act to require coordinated National Institute of 
Standards and Technology science and research activities regarding 
illicit drugs containing xylazine, novel synthetic opioids, and other 
substances of concern, and for other purposes.'', do pass with the 
following

                               AMENDMENT:

             Strike all after the enacting clause and insert the 
      following:

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Testing, Rapid Analysis, and 
Narcotic Quality Research Act of 2023'' or the ``TRANQ Research Act of 
2023''.

SEC. 2. XYLAZINE DETECTION AND ANALYSIS.

    (a) Definitions.--In this section:
            (1) Director.--The term ``Director'' means the Director of 
        the National Institute of Standards and Technology.
            (2) Federal laboratory.--The term ``Federal laboratory'' 
        has the meaning given such term in section 4 of the Stevenson-
        Wydler Technology Innovation Act of 1980 (15 U.S.C. 3703).
            (3) Institute.--The term ``Institute'' means the National 
        Institute of Standards and Technology.
            (4) Institution of higher education.--The term 
        ``institution of higher education'' has the meaning given such 
        term in section 101 of the Higher Education Act of 1965 (19 
        U.S.C. 1001).
            (5) Nonprofit organization.--The term ``nonprofit 
        organization'' means an organization described in section 
        501(c)(3) of the Internal Revenue Code of 1986 and exempt from 
        tax under section 501(a) of such code.
            (6) Xylazine.--The term ``xylazine'' means the nonopioid 
        tranquilizer methyl benzene compound frequently used in 
        veterinary medicine as an emetic and sedative with analgesic 
        and muscle relaxant properties.
    (b) In General.--The Director shall--
            (1) support intramural basic measurement science and 
        research of the Institute to advance--
                    (A) analytical methods to identify, understand, 
                differentiate, and categorize substances containing 
                xylazine, novel synthetic opioids, or other new 
                psychoactive substances;
                    (B) measurement technologies to shorten analysis 
                timelines and enhance narcotic and opioid detection and 
                analysis capabilities;
                    (C) new data tools, techniques, and processes to 
                identify and publicly disclose relevant information 
                concerning substances containing xylazine, novel 
                synthetic opioids, or other new psychoactive 
                substances; and
                    (D) such other areas as the Director determines to 
                be critical to the development and deployment of 
                technologies to measure and analyze the presence of 
                xylazine, novel synthetic opioids, and other new 
                psychoactive substances;
            (2) support activities to inform and expand the development 
        of near-real time spectrometry capabilities regarding xylazine, 
        novel synthetic opioids, and other new psychoactive substances;
            (3) convene and consult with organizations engaged in the 
        analysis of new psychoactive substances to develop coordinated 
        strategies and voluntary best practices for the safe handling, 
        transport, data-sharing, and analysis of substances containing 
        xylazine, novel synthetic opioids, or other new psychoactive 
        substances, including--
                    (A) the Drug Enforcement Administration;
                    (B) the Centers for Disease Control and Prevention;
                    (C) the National Institute on Drug Abuse;
                    (D) Federal laboratories;
                    (E) States and territories;
                    (F) State fusion centers;
                    (G) the private sector;
                    (H) intergovernmental organizations;
                    (I) institutions of higher education, and
                    (J) nonprofit organizations;
            (4) establish or expand collaborative partnerships or 
        consortia with other government agencies and persons engaged in 
        related research and development, such as institutions of 
        higher education, Federal laboratories, public health agencies, 
        intergovernmental organizations, and the private sector, to 
        enhance narcotic and opioid detection and analysis capabilities 
        regarding xylazine, novel synthetic opioids, and other new 
        psychoactive substances; and
            (5) encourage graduate and post-graduate research to 
        include detection and identification of xylazine and other new 
        psychoactive substances in relevant course studies when 
        practicable.
    (c) Controls.--In carrying out activities under this section, the 
Director shall ensure proper security controls are implemented to 
protect sensitive information, as the Director considers appropriate 
and consistent with applicable provisions of law.
    (d) Report.--Not later than 1 year after the date of the enactment 
of this Act, the Director shall submit to the Committee on Commerce, 
Science, and Transportation of the Senate and the Committee on Science, 
Space, and Technology of the House of Representatives a report on the 
implementation of this section. Such report may include recommendations 
for legislative action to improve the ability of the Director to carry 
out this section.

SEC. 3. STUDY ON UNITED STATES GOVERNMENT TECHNOLOGIES AND ANALYTICAL 
              METHODS TO DETECT AND IDENTIFY NEW PSYCHOACTIVE 
              SUBSTANCES.

    (a) Study.--
            (1) In general.--The Comptroller General of the United 
        States shall conduct a study of the capabilities of the Federal 
        Government to respond to the threats of new psychoactive 
        substances such as xylazine.
            (2) Matters evaluated.--The study conducted pursuant to 
        paragraph (1) shall include an evaluation of the following:
                    (A) The capabilities, including technologies and 
                analytical methods, of Federal, State, and local 
                agencies to detect and identify new psychoactive 
                substances such as xylazine.
                    (B) An analysis of timeframes for identification 
                and development of technologies and methods to identify 
                new psychoactive substances by Federal, State, and 
                local agencies.
                    (C) Facilities, including laboratories, used by 
                Federal, State, and local agencies for the 
                identification of new psychoactive substances such as 
                xylazine.
                    (D) Federal grant programs to fund new technology 
                development to detect and identify new psychoactive 
                substances.
    (b) Report.--Not later than 2 years after the date of the enactment 
of this Act, the Comptroller General shall submit to the Committee on 
Commerce, Science, and Transportation of the Senate and the Committee 
on Science, Space, and Technology of the House of Representatives a 
report containing the findings of the Comptroller General with respect 
to the study conducted pursuant to subsection (a).

            Attest:

                                                             Secretary.
118th CONGRESS

  1st Session

                               H.R. 1734

_______________________________________________________________________

                               AMENDMENT